This week, findings from a clinical trial of children with high-risk Hodgkin lymphoma found the anti-CD30 antibody drug brentuximab vedotin effectively reduces side effects and radiation exposure. Replacement of the chemotherapy drug vincristine with brentuximab vedotin in frontline treatment led to an overall three-year survival rate of 99%, and 35% of patients were spared radiation.
In other news, researchers identified potential genetic predictors of immunotherapy response in metastatic bladder cancer. The team identified two gene signatures associated with treatment response: one which triggered an adaptive immunity response and a second that was associated with pro-tumorigenic inflammation. The ratio of adaptive immunity to pro-tumorigenic inflammation was found to be predictive of clinical outcomes.
Adult survivors of adolescent and young adult cancers face considerable financial hardship, according to a study published in the Journal of the National Cancer Institute. According to the results, survivors were more likely to report material and behavioral financial hardship and were more likely to report a greater magnitude juxtaposed to their non-cancer counterparts.
Finally, some patients with metastatic kidney cancer develop asymptomatic brain metastases, which were associated with poorer outcomes, according to a study. “Brain imaging is routinely obtained for kidney cancer patients with symptoms that suggest central nervous system metastases, but none of the patients with brain metastases included here were symptomatic,” added senior author Martin H. Voss, MD.